Suppr超能文献

急性静脉曲张出血患者内镜检查辅助药物的比较:一项系统评价和网状Meta分析

Comparison of drugs facilitating endoscopy for patients with acute variceal bleeding: a systematic review and network meta-analysis.

作者信息

Zou Ziyuan, Yan Xinwen, Lu Huanpeng, Qi Xingshun, Gu Ye, Li Xun, Wu Bin, Qi Xiaolong

机构信息

CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou 730000, China.

The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

出版信息

Ann Transl Med. 2019 Dec;7(23):717. doi: 10.21037/atm.2019.12.26.

Abstract

BACKGROUND

We aimed to compare the efficacy of different drugs facilitating endoscopy in patients with acute variceal bleeding.

METHODS

Databases were searched to identify randomized controlled trials which compared the efficacy of vasoactive drugs (vasopressin, terlipressin, octreotide, somatostatin) with placebo or each other. The primary outcomes were 6-week and 5-day mortality. Secondary outcomes were 5-day rebleeding, control of initial bleeding and adverse events. Pairwise and network meta-analysis were performed.

RESULTS

We identified 14 RCTs involved 2,187 patients. Four drugs had comparable clinical efficacy in all involving outcomes, except for adverse events. However, we do exhibit a superiority when vasopressin (OR, 4.40; 95% CI: 1.04-19.57), terlipressin (OR, 4.58; 95% CI: 1.63-13.63), octreotide (OR, 5.79; 95% CI: 2.41-16.71) and somatostatin (OR, 5.15; 95% CI: 1.40-27.39) were compared to placebo respectively as for initial hemostasis. In addition, only octreotide was more effective than placebo in decreasing 5-day rebleeding (OR, 0.44; 95% CI: 0.22-0.90). Meanwhile, octreotide was shown to have the highest probability ranking the best to improve initial hemostasis (mean rank =1.8) and carries a lowest risk of adverse events (9.1%) and serious adverse events (0.0%) compared to other drugs.

CONCLUSIONS

Balanced with curative effect and tolerability, octreotide may be the preferred vasoactive drug facilitating endoscopy.

摘要

背景

我们旨在比较不同药物在急性静脉曲张出血患者中辅助内镜检查的疗效。

方法

检索数据库以识别比较血管活性药物(血管加压素、特利加压素、奥曲肽、生长抑素)与安慰剂或相互之间疗效的随机对照试验。主要结局为6周和5天死亡率。次要结局为5天再出血、初始出血控制及不良事件。进行成对和网状荟萃分析。

结果

我们识别出14项随机对照试验,涉及2187例患者。除不良事件外,四种药物在所有涉及的结局中临床疗效相当。然而,当血管加压素(比值比,4.40;95%置信区间:1.04 - 19.57)、特利加压素(比值比,4.58;95%置信区间:1.63 - 13.63)、奥曲肽(比值比,5.79;95%置信区间:2.41 - 16.71)和生长抑素(比值比,5.15;95%置信区间:1.40 - 27.39)分别与安慰剂比较初始止血情况时,我们确实显示出优势。此外,仅奥曲肽在减少5天再出血方面比安慰剂更有效(比值比,0.44;95%置信区间:0.22 - 0.90)。同时,与其他药物相比,奥曲肽显示出在改善初始止血方面排名最佳的概率最高(平均秩次 = 1.8),且不良事件风险最低(9.1%)和严重不良事件风险最低(0.0%)。

结论

综合疗效和耐受性,奥曲肽可能是辅助内镜检查的首选血管活性药物。

相似文献

3
Terlipressin for acute esophageal variceal hemorrhage.
Cochrane Database Syst Rev. 2003(1):CD002147. doi: 10.1002/14651858.CD002147.
6
Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis.
Gastroenterology. 2003 May;124(5):1277-91. doi: 10.1016/s0016-5085(03)00269-5.
8
Systematic review: terlipressin in acute oesophageal variceal haemorrhage.
Aliment Pharmacol Ther. 2003 Jan;17(1):53-64. doi: 10.1046/j.1365-2036.2003.01356.x.
9
Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients.
Cochrane Database Syst Rev. 2002(1):CD002233. doi: 10.1002/14651858.CD002233.
10
Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):587-598. doi: 10.1016/S2468-1253(19)30090-1. Epub 2019 May 29.

引用本文的文献

1
The current applications and future directions of terlipressin.
Hepatol Commun. 2025 Apr 3;9(4). doi: 10.1097/HC9.0000000000000685. eCollection 2025 Apr 1.
3
Incidence and type of adverse events in patients with cirrhosis receiving terlipressin: A systematic review and meta-analysis.
Hepatol Commun. 2024 Sep 18;8(10). doi: 10.1097/HC9.0000000000000526. eCollection 2024 Oct 1.
5
Vasoactive Drug Therapy and Clinical Nursing of Patients with Cardiovascular Disease.
Contrast Media Mol Imaging. 2022 Sep 21;2022:5659513. doi: 10.1155/2022/5659513. eCollection 2022.
6
Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 10;4(4):CD013155. doi: 10.1002/14651858.CD013155.pub2.

本文引用的文献

1
3
New Developments in Managing Variceal Bleeding.
Gastroenterology. 2018 May;154(7):1964-1969. doi: 10.1053/j.gastro.2018.02.023. Epub 2018 Mar 2.
4
Pharmacologic prevention of variceal bleeding and rebleeding.
Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5.
5
Endoscopic treatments for portal hypertension.
Hepatol Int. 2018 Feb;12(Suppl 1):91-101. doi: 10.1007/s12072-017-9828-8. Epub 2017 Nov 7.
6
The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Hepatol Int. 2018 Feb;12(Suppl 1):1-10. doi: 10.1007/s12072-017-9827-9. Epub 2017 Oct 24.
7
Acute variceal bleeding: risk stratification and management (including TIPS).
Hepatol Int. 2018 Feb;12(Suppl 1):81-90. doi: 10.1007/s12072-017-9804-3. Epub 2017 Jun 20.
9
Trials and Tribulations: The Prevention of Variceal Rebleeding.
Gastroenterology. 2015 Sep;149(3):528-31. doi: 10.1053/j.gastro.2015.07.026. Epub 2015 Jul 27.
10
Assessing key assumptions of network meta-analysis: a review of methods.
Res Synth Methods. 2013 Dec;4(4):291-323. doi: 10.1002/jrsm.1085. Epub 2013 Aug 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验